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ABSTRACT We have studied the stoichiometry of the
binding of the long a-neurotoxins from the venom of
Dendroaspis viridis (a-dendrotoxin) and Naja naja siamensis
(a-cobratoxin) to the membrane-bound acetylcholine receptor
(AcChoR) from Torpedo californica electric organ. The number
of toxin molecules bound to one AcChoR molecule was deter-
mined by simultaneous-quantitative gas-phase microsequenc-
ing of all the amino acid sequences present in AcChoR-a-
neurotoxin complexes. This method permits the use of homo-
geneous (nonradiolabeled) preparations of native toxins to
obtain molar ratios of neurotoxin-receptor complexes. The
stoichiometry obtained for a-cobratoxin was 2.1 ± 0.2 (n = 4),
in agreement with the accepted view that a-cobratoxin, like
a-bungarotoxin, binds to the two a subunits, which are
constituent polypeptides of the AcChoR molecule. a-
Dendrotoxin gave a stoichiometry of 4.1 ± 0.5 (n = 12);
therefore, the AcChoR molecule contains four binding sites for
this a-neurotoxin, two of which are recognized by a-
cobratoxin. In support of this contention we have also found
that when the AcChoR is saturated with a-bungarotoxin,
addition of a-dendrotoxin markedly accelerates the dissocia-
tion of the bound a-bungarotoxin, demonstrating that the
occupancy of the additional two sites by the latter toxin
influences and decreases the affinity of the former toxin for its
two binding sites. The fact that the AcChoR molecule is a
pseudosymmetric complex of five highly homologous peptides
suggests the possibility that as many as five binding sites for
cholinergic ligand could be present, one on each subunit.
The nicotinic acetylcholine receptor (AcChoR) from Torpedo
electric organ is a complex pentameric molecule formed by
four highly homologous proteins in a stoichiometry a2Pfy8
(reviewed in ref. 1). The AcChoR structure is highly con-
served along vertebrate evolution; nicotinic receptors from
electric organs and muscle of distant animal species are
consistently pseudosymmetric pentamers of four homolo-
gous subunits, and subunits of corresponding molecular
weight from different AcChoRs are also highly homologous
(2-11). Therefore, all the subunits of the AcChoR molecule
studied so far are derived from a common ancestor, by means
of gene duplications, which occurred very early during
vertebrate evolution (2-4).
The AcChoR molecule contains a cation channel, whose
opening and closing are controlled by the binding of cholin-
ergic agonists and antagonists (reviewed in ref. 1). A major
goal in elucidating the mechanism of AcChoR function has
been to define the ligand binding events leading to activation
of the ion channel. Both electrophysiological (12-15) and
stopped-flow (16) studies indicated that the opening of the
channel results from acetylcholine binding to two low-affinity
sites, which operate somehow in a cooperative fashion.
Ligand binding also causes the AcChoR to slowly become
desensitized to a state characterized by inability of the
channel to open and by high affinity for ligands (17-20). Since
each of the two a subunits has a high-affinity binding site for
cholinergic ligands (reviewed in ref. 1), several models of the
linear type have been proposed in which both activation and
desensitization of the receptor are controlled by ligand
binding to these two sites and trigger physiological effects by
sequential mechanisms involving multiple conformational
changes with concomitant alterations in ligand affinity (re-
viewed in ref. 1). However, the relatively early divergence of
the genes encoding the AcChoR subunits, as well as the
extremely high degree of homology among corresponding
subunits from distant animal species, suggests that the
AcChoR subunits evolved separately to perform different
functions (such as activation and desensitization) and that
each subunit could in principle have an independent ligand
binding site.
The long a-neurotoxins from snake venoms are a group of
polypeptide cholinergic antagonists that are useful for study
of the AcChoR binding sites, since they bind in a specific and
very slowly reversible fashion (21). The only a-neurotoxins
that have been extensively used are a-cobratoxin (a-Ntx)
from the venom of Naja naja species and a-bungarotoxin
(a-B'tx) from Bungarus multicinctus. a-Ntx is widely used as
a ligand for affinity chromatography to purify the AcChoR
from various sources (reviewed in ref. 1). a-Btx has been
shown to bind to the a subunits (22, 23), and since the binding
of a-Btx and a-Ntx is mutually exclusive and they both
inhibit photoaffinity labeling of the a-subunit (24, 25), it is
believed that also a-Ntx binds to the high-affinity binding
sites for cholinergic ligands present on the a subunits.
Results, obtained with a-Ntx cross-linked to the AcChoR
subunits and with an electron microscopic approach using
a-Ntx complexed to biotin-avidin, support the notion that
also a-Ntx binds to the a subunits (26, 27). a-Ntx and a-Btx
bind to the AcChoR molecule with a stoichiometry of 2:1
(reviewed in ref. 1).
If binding sites for acetylcholine were to exist on all
AcChoR subunits, one might expect that some other snake
toxins could bind to some ofthe sites not recognized by a-Ntx
and a-Btx, or to all of them. Such toxins would be valuable
tools to determine the number and localization of the cho-
linergic binding sites present on subunits other than the a
peptide.
Here we report studies of the binding stoichiometry of the
long a-neurotoxin from Dendroaspis viridis (a-Dtx) and
compare it with similar studies of a-Ntx. The binding of
native toxins was measured by simultaneous-quantitative
determination of the amino-terminal sequences present in the
AcChoR-toxin complexes. We found that whereas four
molecules of a-Dtx can complex with the AcChoR, only two
Abbreviations: AcChoR, acetylcholine receptor; a-Dtx, a-
dendrotoxin; a-Ntx, a-cobratoxin from Naja naja siamensis; a-Btx,
a-bungarotoxin; 1251-a-Btx, a-Btx radiolabeled with 1251; BrAcCho,
bromoacetylcholine.
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molecules of a-Ntx can bind to one AcChoR molecule in a
slowly reversible fashion. Therefore, the AcChoR molecule
contains at least four binding sites for these cholinergic
antagonists of which only two are recognized by a-Ntx and
a-Btx. Ternary complexes between AcChoR and both a-Btx
and a-Dtx are possible, as demonstrated by the increase of
dissociation rate of 125I-labeled a-Btx (125I-a-Btx) bound to
AcChoR when a-Dtx is present.
MATERIALS AND METHODS
a-Dtx and a-Ntx Purification. a-Dtx was purified from
Dendroaspis viridis (Sigma) by the method of Shipolini et al.
(28). a-Ntx was purified from Naja naja siamensis venom
(Biotoxins, St. Cloud, FL) as described by Ong and Brady
(29). The peptide composition of the column fractions was
assessed by NaDodSO4/polyacrylamide gel electrophoresis
(30) using slab gels containing exponential or linear gradients
of acrylamide from 15 to 22.5%. The identity and purity of
isolated toxins was assessed by amino-terminal amino acid
sequence (see below).
Protein Determination. Protein concentrations were mea-
sured by the method of Lowry et al. (31) or with the flu-
prescamine assay (32).
AcChoR Purification. Membrane-bound AcChoR was pre-
pared from T. californica electric organs as described (33)
and submitted to two cycles of alkali extraction (34, 35) to
remove extrinsic membrane proteins. The concentration of
a-Btx binding sites was measured by the DEAE-disk assay of
Schmidt and Raftery (36) with '25I-a-Btx (New England Nu-
clear). The specific activity of '25I-a-Btx, isotopically diluted
with a-Btx purified as described (29) was measured by the
method ofBlanchard et al. (37). NaDodSO4/gel electrophoresis
ofAcChoR preparations was performed according to Laemmli
(30), using gel slabs 1 mm thick and containing 8.75%
acrylamide.
Preparations of purified membrane-bound AcChoR had
specific activities ranging between 4 and 7.5 nmol of a-Btx
binding per mg of protein. Upon NaDodSO4/gel electropho-
resis the four AcChoR subunits were the only major protein
bands present. A protein of Mr 'z94,000 and components of
Mr <30,000 (which are believed to be degradation products
of the AcChoR subunits) were occasionally present.
Formation of Toxin/AcChoR Complexes. Aliquots ofmem-
brane-bound AcChoR in 10 mM sodium phosphate buffer, pH
7.0, were incubated for 1 hr at 60°C with a 5- to 10-fold excess
of aDtx or a-Ntx. The AcChoR concentration was deter-
mined, following Triton X-100 solubilization, from the bind-
ing of 125I-a-Btx, assuming that two a-Btx molecules bound
to one AcChoR molecule under these conditions. The mem-
brane fragments were washed and centrifuged twice in a
Beckman Microfuge at 6°C for 15 min using ice cold 50 mM
ammonium bicarbonate at pH 9. Preliminary experiments
demonstrated that this volatile buffer did not influence the
dissociation rate of a-Btx-AcChoR complexes. The washed
membrane-bound AcChoR-toxin complexes were solubil-
ized with 1.5% NaDodSO4 in 50mM ammonium bicarbonate
and lyophilized several times to eliminate the buffer. The
NaDodSO4 had been recrystallized twice from hot ethanol.
Amino-Terminal Amino Acid Sequence Analysis. The
lyophilized AcChoR-toxin complexes with NaDodSO4 were
dissolved in glass-distilled water and submitted to amino-
terminal amino acid sequencing by automated Edman deg-
radation in a gas-phase sequencer (Applied Biosystems,
Foster City, CA). Phenylthiohydantoin-derivatized amino
acids were identified by HPLC on an IBM Cyano column
(38).
Effect of a-Dtx on the Dissociation Rate of a-Btx-AcChoR
Complexes. 251-a-Btx-AcChoR complexes were formed by
incubating membrane bound AcChoR (1-14 ,uM in 10 mM
phosphate buffer, pH 7.0) for 1 hr at 6°C with a 2-fold excess
of radiolabeled toxin. The unreacted toxin was washed away
by diluting the reaction mixture with 30 ml of the same buffer
and pelleting the membrane fragments at 19,000 rpm for 20
min in a Sorvall SS-34 rotor. The washed complexes were
resuspended in a minimal volume (-300 ,ul) of the same
buffer, and aliquots of 0. 1-0.8 nmol ofAcChoR (measured as
a-Btx binding sites) were incubated at 60°C with a 10-fold
excess of either unlabeled a-Btx or a-Dtx. The final AcChoR
concentration was 1 ,uM. Aliquots ofthe mixtures were taken
at time intervals and pipetted onto DEAE disks. The disks
were washed as described (36) and the '25I-a-Btx still bound
to the AcChoR was determined using a Beckman gamma
counter. Previous experiments (not reported here) showed
that membrane-bound AcChoR binds quantitatively to
DEAE disks. The dissociation rate of the a-Btx-AcChoR
complexes was calculated from the amount of radioactive
toxin still bound to AcChoR at the various time intervals,
using an exponential fitting program.
RESULTS
Purification of a-Dtx and a-Ntx. Different toxins capable of
interference with cholinergic transmission can be isolated
from D. viridis venom. The elution profiles we obtained in
these studies for the three chromatographic steps of the
purification procedure were in excellent agreement with
those reported (28). The final a-Dtx peak was desalted,
lyophilized, and submitted to amino-terminal amino acid
sequencing. The sequence obtained corresponded to that of
a-Dtx [toxin 4.9.3 of Banks et al. (28, 39)]. Marginal amounts
(<4%) of the short a-neurotoxin designated by Banks et al.
(39) as toxin 4.9.6 were consistently present in a-Dtx prep-
arations. This toxin can bind to AcChoR (data not shown),
and since its sequence is known (40), this was taken into
consideration in the analysis of the sequences present in the
a-Dtx-AcChoR complexes. Purified a-Ntx preparations
were consistently found to be free of any contaminating
material by sequence analysis, which yielded only the known
amino acid sequence (21).
Determination of the Stoichiometry of a-Dtx and a-Ntx
Binding to AcChoR. This was achieved by simultaneous
quantitative determination of the amino acid sequences
present in washed toxin-AcChoR complexes. In Fig. 1 the
amino-terminal sequences of the four AcChoR subunits are
compared with the corresponding segments of a-Dtx (A) and
a-Ntx (B). For quantitation of multiple sequences, careful
evaluation of the repetitive yield of the Edman degradation
A
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5
S E 1 E T R L V A N L L E N Y
8 S V M E D T L L S V L F E T Y
y E N E E G R L I E K L X G. G Y
6 V N E E EI 1, I N D L L I V N
a-Dtx R T C Y K T P S V K P E r c P
B
1 2 3 4 5 6 7 8 9 0 1 2 3 4 5
Li S E H F T R L V A N L L E N Y
5 S V M E D T L L S V L F E T Y
Y E N E E G R L I E K L L G G Y
6 V N E E F. 1 , I N D L L I V NJ
a-Ntx I R C F 1 T P D) V r S K D C P
FIG. 1. Amino-terminal amino acid sequences of the four Ac-
ChoR subunits a, 83, y, and 8 (from ref. 2) and of a-Dtx (A) and a-Ntx(B). The sequences of the toxins are from refs. 39 and 21.
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during each sequence determination is essential, and this can
be obtained from the sequences of the AcChoR subunits, by
comparing (using the single-letter notation for each amino
acid residue with a subscript to designate the position of that
residue from the amino terminus) V1 (8) with 1/2 of V8 (a2),
1/2 of N2 (Y, 8) with Ng (8) and L7 (a2, 13, y, 8) with L11 (a2,
/3, y, 8). In the case of a-Dtx, the binding stoichiometry can
be calculated best by comparing at least two of the following
residues: R1 with 1/4 of R6 (a2, y, 8); T2 with 1/2 of T5 (a2);
Y4 with 1/5 of E4 (a2, a, Y, 8); Y4 with M3 (O), D5 (), 1/5 of
L7 (a2, /3, y, 8) and 1/4 of V8 + I8 (a2, y, 8). When residues
from different cycles are compared, they must be normalized
using the repetitive yield of that particular sequence run,
calculated as described above. The values obtained were
averaged to obtain the final a-Dtx/AcChoR stoichiometry.
The a-Ntx/AcChoR stoichiometry was obtained in a similar
fashion by comparing the following residues: I, with V1 (8);
R2 with 1/4 of R6 (a2, 'y, 8); I1 and I5 with 1/2 of I8 (y, 8); F4
with 1/5 of E4 (a2, /3, y, 8) and with F12 (,/); F4 and 15 with 1/5
of L7 (a2, , Y, 86).
The stoichiometry values were obtained for a-Dtx and
a-Ntx in different experiments, using different AcChoR and
toxin preparations. The average value obtained in the pres-
ence of saturating amounts of toxins (molar ratio 5-80:1) was
4.1 + 0.5 (n = 12) for a-Dtx and 2.1 ± 0.2 (n = 4) for a-Ntx.
When subsaturating amounts of a-Dtx were used, the amount
of bound a-Dtx increased linearly and reached a plateau of
approximately four molecules of a-Dtx bound per AcChoR
molecule at a toxin/AcChoR concentration of 4:1 (AcChoR,
2 1LM; a-Dtx, 8 ,uM) (Fig. 2).
Effect of a-Dtx on the Dissociation Rate of a -Btx-AcChoR
Complexes. The basal dissociation rate of the complexes
between 1251-a-Btx and AcChoR was measured in the pres-
ence of an excess of unlabeled a-Btx for incubation periods
of up to 48 hr. The half-life of the complexes was found to be
>250 hr, in good agreement with the accepted notion that this
toxin forms very slowly reversible complexes (37). When
unlabeled a-Dtx was present, the dissociation rate was
markedly enhanced, and the half-life was reduced to 6.15 +
2.13 hr (n = 6) (Fig. 3).
DISCUSSION
A major goal in the elucidation of AcChoR function is to
define the events mediated by ligand binding that lead to
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FIG. 2. Concentration dependency of a-Dtx binding to mem-
brane-bound AcChoR. The amount of bound a-Dtx to one AcChoR
molecule increases linearly with the toxin concentration until it
reaches saturation when four a-Dtx molecules are bound, when the
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FIG. 3. Effect of the presence of unlabeled a-Dtx (A) or a-Btx (n)
on the dissociation rate of complexes formed between l25l-a-Btx and
membrane-bound AcChoR. The basal rate of dissociation of 125I-a-
Btx is very slow, with a half-life >250 hr. When a-Dtx is present, the
dissociation rate is markedly enhanced (half-life in this experiment,
4.4 hr; correlation coefficient, 0.973).
of paramount importance to define the number, location, and
function of all binding sites for cholinergic ligands. Here we
directly demonstrate the existence offour binding sites on the
AcChoR molecule, obtained from the binding of a-Dtx, an
irreversible cholinergic ligand.
It has generally been assumed that activation and desen-
sitization are controlled by two quasi-identical binding sites
located on the two a subunits present in the AcChoR
molecule (reviewed in refs. 1 and 16). This assumption was
based on the facts that (i) the a subunits can be labeled with
high affinity by cholinergic affinity reagents, such as
(maleimidobenzyl)trimethyl ammonium chloride (24, 41) and
bromoacetylcholine (BrAcCho) (25, 42-44) by virtue of the
existence of a readily reducible disulfide bond near the site,
and (ii) the a subunit binds a-Btx (22, 23). Many attempts
have been made to compare the in vitro binding of cholinergic
ligands with the affinity and rate characteristics predicted for
the activating binding site from electrophysiological (12-15)
and stopped-flow (16) experiments. A major discrepancy was
consistently found between the apparent dissociation con-
stant measured by direct ligand binding in vitro and those
characterizing the permeability response (reviewed in ref. 1).
This led to proposals of complex ligand binding mechanisms,
involving sequential transitions of affinity states (reviewed in
refs. 1 and 16).
The demonstration that all the peripheral receptors studied
so far are pseudosymmetric pentamers of highly homologous
subunits (2-4, 11) supports the notion that homologous
binding domains could exist on some or possibly all the
subunits. An indication in favor of this possibility was the
observed labeling of more than one subunit by cholinergic
affinity reagents (antagonists) that do not depend on disulfide
bound reduction (45, 46). Furthermore, a low-affinity site(s)
for agonists that is distinct from the well-documented high-
affinity sites on the a subunit has been demonstrated by
spectroscopic methods (47-49). The equilibrium and kinetic
properties of the low-affinity site(s) are those expressed for
a site involved in channel opening (47) and their properties
are not influenced by AcChoR desensitization (48). Cholin-
ergic agonists can still bind to these low-affinity sites with the
same characteristics of affinity and rate after the two a
subunits have been covalently labeled by BrAcCho (49). This
suggests that the high-affinity sites on the a subunits are
involved only or preferentially in inactivation processes such
as desensitization. It is, therefore, crucial to measure by
some direct method the number of binding sites for cholin-
ergic ligands present on the AcChoR molecule. This question
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cannot be answered by equilibrium binding studies or by the
use of affinity ligands because stoichiometric binding to the
low-affinity sites (Kd for acetylcholine -75 AM, Kd for
carbamoylcholine "1 mM) would require the use of high
concentration of radioactive ligand, causing major back-
ground problems. In addition, most ofthe affinity labels so far
used require the presence of a disulfide bond in close
proximity to the binding site, and other results (50) seem to
indicate that the affinity-label (maleimidobenzyl)trimethyl
ammonium chloride can bind to cysteine residues that are
present only in the a subunit (51).
The a-neurotoxins are good ligands to study the binding-
site stoichiometry, since they form very slowly reversible
complexes with the AcChoR. Because of their hydrophilic
nature the tinbound toxin can be efficiently washed away
resulting in minimal nonspecific binding. a-Dtx is a cholin-
ergic antagonist closely related to a-Ntx and a-Btx because
it belongs to the same protein family and is highly homolo-
gous to them (21, 39). These toxins are powerful blockers of
muscle and electric organ AcChoR by virtue of their ability
to bind to the two a subunits (22, 23, 26, 27) in a competitive
fashion with acetylcholine, carbamoylcholine, curare, and
other classic cholinergic ligands (21, 52). a-Btx binds to a
segment of the a subunit very close to or overlapping with the
segment containing a cysteine residue labeled by cholinergic
labels (53).
a-Dtx and a-Ntx are peptide toxins 72 residues long. The
sequence of the first 15 residues is reported in Fig. LA and B.
They both have residues that allow good quantitative com-
parison either with identical residues in the AcChoR se-
quence or with residues known to give a similar yield in the
Edman degradation. Determination of toxin-AcChoR stoi-
chiometry by simultaneous-quantitative sequencing of all the
proteins present in the washed complexes has the following
three major advantages in comparison with methods that
utilize radiolabeled derivatives of the toxin: (i) it permits the
use of homogeneous preparations of native toxin, never
exposed to the rather harsh oxidizing conditions used for
radiolabeling; (ii) it directly measures the amount of each
peptide and their ratios and eliminates the need of determin-
ing protein content and specific activity of radiolabeled
toxins, which are seldom highly accurate; (ii) the amounts of
the different peptides are measured at multiple steps in the
-sequence, yielding multiple-independent determinations of
the peptide stoichiometry of each toxin-AcChoR complex.
Using radiolabeled derivatives of a-Ntx and a-Btx, these
toxins have been found to bind to the AcChoR up to a
maximum of 8 nmol of toxin per mg of pure AcChoR protein
(reviewed in ref. 1). Since the Mr of the toxin is ~"8000 (21)
and that of AcChoR is ==270,000 (51), this corresponds to a
stoichiometry of two toxin molecules bound to one AcChoR
molecule, as expected for toxins that bind to the a subunits.
In excellent agreement with these reports, we directly mea-
sured a binding stoichiometry for the native a-Ntx of 2.1 +
0.2.
In spite of the considerable sequence homology with other
snake a-neurotoxins (39), a-Dtx contains two amino acid
substitutions at positions invariant in other a-neurotoxins. A
glutamic acid replaces an invariant lysine at position 29, and
a second glutamic acid occurs at position 43, which is always
uncharged in the other a-neurotoxins (i.e., valine, isoleucine,
or threonine). This region of the molecule (residues 24-39) is
believed to be essential for function (54-56), these substitu-
tions, involving a change of three in the net charge, might be
expected to cause different binding properties. In agreement
with this prediction, when the same approach used for a-Ntx
was applied for measurement of the number of binding sites
recognized by a-Dtx, a stoichiometry of 4:1 was found. Since
a-Dtx can fully inhibit the binding of a-Btx to AcChoR (57),
this means that a-Dtx can recognize two extra sites in
addition to those on the a subunits. This point is further
proven by the ability of a-Dtx to greatly accelerate the
dissociation of bound 125I-a-Btx from the AcChoR (Fig. 3).
This effect is readily explained if a-Dtx can still bind to
AcChoR saturated with a-Btx and form ternary complexes.
As a result of a-Dtx binding to the sites not recognized by
a-Btx, a conformational change must occur that modifies the
affinity characteristics of the binding sites to which a-Btx is
bound, and a-Btx is more quickly released.
Since a-Ntx and a-Btx bind to the a subunits, the other two
cholinergic sites recognized by a-Dtx could be on any of the
other three peptide components of the AcChoR. The fact that
all the AcChoR subunits are highly homologous raises the
possibility that as many as five potential binding sites for
cholinergic ligands could exist, one on each subunit. A fifth
site could either be unrecognized by a-Dtx or bind with lower
affinity in a reversible fashion so that a-Dtx could dissociate
during the washing procedures used.
It is conceivable that a-Btx and a-Ntx could also bind in
reversible fashion to low-affinity sites other than those on the
a subunits and that such binding cannot be detected by the
conventional assays devised for measuring slowly reversible
binding. In support of this are the following findings: (i) using
affinity derivatives of a-Btx and a-Ntx, other subunits were
labeled in addition to a, although to a lesser extent (26, 58,
59); (ii) in the brain low-affinity sites for a-Ntx and a-Btx
have been demonstrated, in addition to the well-documented
high-affinity sites and in equivalent number (60). The binding
to these low-affinity sites consistently impairs cholinergic
function (61, 62) whereas the binding to the high-affinity sites
is generally functional but silent. a-Dtx blocks AcChoR
function in neuronal systems that are not sensitive to a-Btx
blockade, such as the frog spinal cord (63) and the snail
neurons (64). In addition, the complexes that a-Dtx forms
with neuronal AcChoR are more stable than those formed by
a-Btx (57). These findings support the notion of a broader
binding specificity of a-Dtx, which would, therefore, recog-
nize and bind with high affinity to sites that a-Ntx and a-Btx
bind with much lower affinity or not at all. In support of this
contention, a-Dtx has been demonstrated to bind to twice as
many sites as a-Btx in the sympathetic cell line PC12 (57).
Since the high-affinity binding of a-Ntx and a-Btx to neurons
is in general functionally silent (reviewed in ref. 65), persist-
ent doubts were raised as to whether the a-Btx binding
component was, in fact, an AcChoR. These doubts were
solved by the demonstration (65) that the a-Btx binding
component(s) isolated from different areas of avian brain are
multisubunit-complex proteins at least partially homologous
to peripheral AcChoRs and carrying high-affinity sites for
BrAcCho. Interestingly, the high-affinity site for BrAcCho is
located on a subunit different from the one which, by
molecular weight and sequence homology, was identified as
a. The BrAcCho binding component can be cross-linked by
a-Btx by using dimethysuberimidate (66) and has a Mr of
56,000, similar to the peripheral (3 subunits to which it could
be homologous. These findings raise the interesting possibil-
ity that brain AcChoR works by a mechanism somehow
different from peripheral AcChoR, involving multiple binding
sites but with corresponding sites located on different sub-
units.
From all the above considerations, muscle and neuronal
AcChoRs appear to be as complex proteins carrying multiple
homologous domains and multiple binding sites for cholin-
ergic ligands, possibly one for each subunit. All these sites
could bind agonists and antagonists, but with a spectrum of
affinities and functions different in different AcChoRs. At
low-ligand concentration only high-affinity sites are revealed,
both in terms of their number and of their effect(s). Only using
special ligands with broad specificity, such as a-Dtx, or
suitably high concentrations of the other ligands can one
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reveal and study the low-affinity sites that are associated with
channel activation and, therefore, normal physiological func-
tion.
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